Strategic Partnerships PetMedix has secured a multi-year partnership with Boehringer Ingelheim and completed a notable Series B round with prominent investors including Tencent and Cambridge Innovation Capital, indicating strong institutional support and potential for co-development opportunities and new channel partnerships.

Investment Momentum With a $37M Series B and ongoing recruitment, PetMedix is in a growth phase focused on advancing its Ky9 platform and veterinary antibody therapies, signaling readiness for clinical-stage collaborations, licensing deals, and procurement of specialized R&D services.

Platform Advantage The Ky9 platform enables species-specific, naturally generated antibodies for companion animals, presenting a compelling differentiator for big pharma or niche biotech firms seeking to access a broad veterinary oncology and infectious disease pipeline.

Geographic Reach Based in Cambridge, UK with a global investor base and partnerships, PetMedix offers opportunities for regional sales, joint development programs, and access to European regulatory pathways, as well as potential expansion into the UK’s biotech cluster synergies.

Talent and Growth Active recruitment and a building pipeline imply a growing appetite for external collaborations, contract research, and sponsored research agreements, enabling sales discussions around platforms, services, and early-access programs for veterinary therapeutics.